Clinical trial
Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients…
NCT00031629 · Gynecologic Oncology Group, Other · Completed
Key facts
| NCT number | NCT00031629 |
|---|---|
| Title | Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus |
| Official title | A Phase II Evaluation of Docetaxel and Gemcitabine Plus G-CSF in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Uterine Corpus Sarcoma, Uterine Corpus Leiomyosarcoma |
| Intervention type | Biological, Drug |
| Interventions | Docetaxel, Filgrastim, Gemcitabine Hydrochloride, Pegfilgrastim |
| Enrollment | 51 |
| Start date | Jan 1, 2005 |
| Primary completion | Jul 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 8, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: